医学
2型糖尿病
冲程(发动机)
糖尿病
内科学
肾脏疾病
荟萃分析
钠
疾病
内分泌学
化学
机械工程
工程类
有机化学
作者
Fotios Barkas,S. Filippas Ntekouan,E. Liberopoulos,Haralampos Milionis
标识
DOI:10.1016/j.atherosclerosis.2021.06.132
摘要
Background and Aims: Sotagliflozin, a sodium-glucose contransporter (SGLT)-2/1 inhibitor, has been recently reported to reduce the risk of total stroke in patients with type 2 diabetes (T2D) and chronic kidney disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI